-
Start Preamble
ACTION:
Notice of application.
DATES:
Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before August 6, 2020. Such persons may also file a written request for a hearing on the application on or before August 6, 2020.
ADDRESSES:
Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All request for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.
End Preamble Start Supplemental InformationSUPPLEMENTARY INFORMATION:
In accordance with 21 CFR 1301.34(a), this is notice that on June 4, 2020, Lipomed, 150 Cambridgepark Drive, Suite 705, Cambridge, Massachusetts 02140, applied to be registered as an importer of the following basic class(es) of controlled substances:
Controlled substance Drug code Schedule Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido) 3,3-dimethylbutanoate) 7036 I N-(Adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboximide) 7047 I 1-(5-Fluoropentyl)-1H-indazole-3-carboxamide 7083 I 4-methyl-alpha-ethylaminopentiophenone (4-MEAP) 7245 I N-ethylhexedrone 7246 I 4-chloro-alpha-pyrrolidinovalerophenone (4-chloro-a-PVP) 7443 I α-PHP, alpha-Pyrrolidinohexanophenone 7544 I PV8, alpha-Pyrrolidinoheptaphenone 7548 I Norfentanyl 8366 I The company plans to import the above controlled substances as analytical reference standards for distribution to its customers for research and analytical purposes. Placement of these drug codes onto the company's registration does not translate into automatic approval of subsequent permit applications to import controlled substances. Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized in 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration (FDA)-approved or non-approved finished dosage forms for commercial sale.
Start SignatureWilliam T. McDermott,
Assistant Administrator.
[FR Doc. 2020-14605 Filed 7-6-20; 8:45 am]
BILLING CODE P
Document Information
- Published:
- 07/07/2020
- Department:
- Drug Enforcement Administration
- Entry Type:
- Notice
- Action:
- Notice of application.
- Document Number:
- 2020-14605
- Dates:
- Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before August 6, 2020. Such persons may also file a written request for a hearing on the application on or before August 6, 2020.
- Pages:
- 40687-40687 (1 pages)
- Docket Numbers:
- Docket No. DEA-672
- PDF File:
- 2020-14605.pdf